The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’),
the developer of cancer vaccines based on its patented ImmunoBody™ platform, are pleased
to announce the interim results for Scancell for the six month period ended 31st October 2008
(‘the period’).
Highlights:
- Admitted to Plus markets on 24 September 2008 and raised £1.559,502 on 24th September 2008
- Issue of equity raised £43,999.8 on the 19th of December 2008
- Following the placing of shares in September, the Company has £2,220,479 cash reserves
- Continued make good progress towards its goal of starting Phase 1 clinical trials with SCIB1 in 2010
- Agreement to license key components of SCIB1 from National Institute for Health (‘NIH’) in the final phase of negotiation
- Negotiations to secure development and commercial rights to an injection device to deliver SCIB1 to patients progressing wel
- Experienced Development Advisor appointed for SCIB1
- Presented at the Genesis 2008 Oncology Showcase
David Evans, Non-Executive Chairman of Scancell, commented:
“I am delighted to report a very successful first six months as a public company. In 2008, we raised £1.6m in conjunction with being admitted to Plus markets. The funds raised will provide the ability to further develop Scancell’s core technology; the ImmunoBodyTM platform and to achieve its aim of starting Phase 1 clinical trials of SCIB1 in 2010.”
For further information contact:
Company:
Scancell Holdings Plc - Professor Lindy Durrant/Dr Richard Goodfellow - Tel: 020 7245 1100
Corporate Advisers:
St Helen's Capital Plc - Duncan Vasey/Barry Hocken - Tel: 020 7628 5582
Financial PR:
Hansard Group - Adam Reynolds/Vicky Krause - Tel: 020 7245 1100
View the full results